Emanuele Marra
Overview
Explore the profile of Emanuele Marra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vesci L, Tundo G, Soldi S, Galletti S, Stoppoloni D, Bernardini R, et al.
Nutrients
. 2024 Apr;
16(7).
PMID: 38612971
Crohn's and ulcerative colitis are common conditions associated with inflammatory bowel disease as well as intestinal flora and epithelial barrier dysfunction. A novel fermented (AL0035) herein assayed in a trinitro...
2.
DAcunto E, Muzi A, Marchese S, Donnici L, Chiarini V, Bucci F, et al.
Antibodies (Basel)
. 2024 Jan;
13(1).
PMID: 38247569
The COVID-19 pandemic, once a global crisis, is now largely under control, a testament to the extraordinary global efforts involving vaccination and public health measures. However, the relentless evolution of...
3.
Barbieri S, Cattani F, Sandrini L, Grillo M, Amendola A, Valente C, et al.
Signal Transduct Target Ther
. 2023 May;
8(1):203.
PMID: 37208343
No abstract available.
4.
Aurisicchio L, Brambilla N, Cazzaniga M, Bonfanti P, Milleri S, Ascierto P, et al.
Mol Ther
. 2022 Dec;
31(3):788-800.
PMID: 36575794
The COVID-19 pandemic and the need for additional safe, effective, and affordable vaccines gave new impetus into development of vaccine genetic platforms. Here we report the findings from the phase...
5.
Fattore L, Cafaro G, Di Martile M, Campani V, Sacconi A, Liguoro D, et al.
Oncogene
. 2022 Nov;
42(4):293-307.
PMID: 36418472
BRAF-mutated melanoma relapsing after targeted therapies is an aggressive disease with unmet clinical need. Hence the need to identify novel combination therapies able to overcome drug resistance. miRNAs have emerged...
6.
Milazzo F, Chaves-Sanjuan A, Minenkova O, Santapaola D, Anastasi A, Battistuzzi G, et al.
Mol Ther
. 2022 Sep;
31(2):362-373.
PMID: 36114671
The uneven worldwide vaccination coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and emergence of variants escaping immunity call for broadly effective and easily deployable therapeutic agents. We have...
7.
Giannini G, Ragusa I, Nardone G, Soldi S, Elli M, Valenti P, et al.
Int J Dent
. 2022 Mar;
2022:5007930.
PMID: 35265133
Objective: Periodontitis is a common disorder that leads to the loss of both tooth and personal well-being, contributing to worsen the risk for metabolic and cardiovascular diseases. Recently, probiotics, characterized...
8.
Minenkova O, Santapaola D, Milazzo F, Anastasi A, Battistuzzi G, Chiapparino C, et al.
Mol Ther
. 2022 Feb;
30(5):1979-1993.
PMID: 35167974
As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global emergency, and novel therapeutics are urgently needed. Here we...
9.
Luberto L, Neroni B, Gandini O, Fiscarelli E, Salvatori G, Roscilli G, et al.
Front Microbiol
. 2022 Jan;
12:789774.
PMID: 34975811
The COVID-19 pandemic has highlighted genetic vaccination as a powerful and cost-effective tool to counteract infectious diseases. Invasive fungal infections (IFI) remain a major challenge among immune compromised patients, particularly...
10.
Maffei M, Montemiglio L, Vitagliano G, Fedele L, Sellathurai S, Bucci F, et al.
Biomolecules
. 2021 Dec;
11(12).
PMID: 34944456
COVID-19 is a highly infectious disease caused by a newly emerged coronavirus (SARS-CoV-2) that has rapidly progressed into a pandemic. This unprecedent emergency has stressed the significance of developing effective...